News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
諾誠健華(09969.HK)：奧布替尼已獲澳洲批准用於治療淋巴瘤成年患者
諾誠健華(09969.HK)公布，奧布替尼(宜諾凱，HIBRUKA)已獲澳洲藥品管理局(TGA)批准，用於治療復發或難治性套細胞淋巴瘤(r/r MCL)成年患者。(jl/a)~阿思達克財經新聞網址: www.aastocks.com
Reset
Send
The window will close in 5 seconds
諾誠健華(09969.HK)：奧布替尼已獲澳洲批准用於治療淋巴瘤成年患者
Close
Recommend
2
Positive
4
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

諾誠健華(09969.HK)  -0.350 (-3.188%)    Short selling $1.08M; Ratio 4.392%   公布，奧布替尼(宜諾凱，HIBRUKA)已獲澳洲藥品管理局(TGA)批准，用於治療復發或難治性套細胞淋巴瘤(r/r MCL)成年患者。(jl/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-04 12:25.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.